AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23800194 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Obstetric and Newborn Care (EmONC) package including clean delivery kit, emollient, chlorhexidine, and training of health care providers.
Number of subjects: 0
Study 23800194 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control arm).
Number of subjects: 0
Study 20881844 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 12 mg/day
Number of subjects: 109
Study 20881844 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 18 mg/day
Number of subjects: 109
Study 20881844 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine 800 mg/day
Number of subjects: 109
Study 20881844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 20881844 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 109
Study 20881844 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 109
Study 19376787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 201
Study 19376787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.0 mg kg(‐1)
Number of subjects: 201
Study 17680196 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas compartment block
Number of subjects: 68
Study 17680196 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 68
Study 15151527 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (4 mg day(‐1))
Number of subjects: 8
Study 15151527 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 8
Study 10886043 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen for 8 weeks in H. pylori-positive patients
Number of subjects: 55
Study 10886043 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen for 8 weeks in non-infected patients
Number of subjects: 55
Study 10886043 — intervention group
Group type: COMPARATOR
Intervention: Anti-Helicobacter therapy in controls (D)
Number of subjects: 55
Study 9188352 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management workshops
Number of subjects: 99
Study 9188352 — intervention group
Group type: COMPARATOR
Intervention: No-treatment controls
Number of subjects: 99
Study 1531719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, intradermal hepatitis B vaccination (2 micrograms)
Number of subjects: 88
Study 1531719 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of 2 micrograms i.d.
Number of subjects: 88
Study 1531719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, intradermal hepatitis B vaccination (3 doses at 0, 1, and 6 months)
Number of subjects: 88
Study 1531719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, intradermal hepatitis B vaccination (2 doses)
Number of subjects: 88
Study 1531719 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of 2 micrograms i.d. at month 25
Number of subjects: 88
Study 3893444 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen 200 mg
Number of subjects: 88
Study 3893444 — intervention group
Group type: EXPERIMENTAL
Intervention: pentazocine 30 mg
Number of subjects: 88
Study 3893444 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study 31425224 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermosoftening of the endotracheal tube (ETT)
Number of subjects: 140
Study 31425224 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-thermosoftened ETT)
Number of subjects: 140
Study 29605722 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided biliary drainage (EUS-BD)
Number of subjects: 30
Study 29605722 — intervention group
Group type: COMPARATOR
Intervention: ERCP-guided biliary drainage (ERCP-BD)
Number of subjects: 30
Study 26996595 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR (7 Gy each in three fractions, repeated weekly)
Number of subjects: 37
Study 26996595 — intervention group
Group type: COMPARATOR
Intervention: PDR (70 cGy hourly pulses for 39 hours, total 27 Gy)
Number of subjects: 37
Study 24820395 — intervention group
Group type: EXPERIMENTAL
Intervention: CBFV (Vm, Vs, Vd, rVm) measured at 18 hours post-CPB
Number of subjects: 100
Study 24820395 — intervention group
Group type: EXPERIMENTAL
Intervention: CBFV (Vs, rVm) measured at 18 hours post-CPB
Number of subjects: 100
Study 23732307 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of laninamivir octanoate once daily for 2 days (LO-2)
Number of subjects: 1711
Study 23732307 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of laninamivir octanoate once daily for 3 days (LO-3)
Number of subjects: 1711
Study 23732307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1711
Study 20521635 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigenic cartography analysis of avian H5N1 viruses using hemagglutination inhibition (HI) assay.
Number of subjects: 0
Study 20521635 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterization of antigenic properties using mammalian or avian antisera.
Number of subjects: 0
Study 18983547 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-edge hydrophobic acrylic IOL (Acrysof SA 60 AT)
Number of subjects: 32
Study 18983547 — intervention group
Group type: COMPARATOR
Intervention: Square-edge single-piece PMMA lens (Aurolab SQ 3600)
Number of subjects: 32
Study 16640685 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc excision of proximal nail fold with nail plate avulsion (Group II)
Number of subjects: 30
Study 16640685 — intervention group
Group type: COMPARATOR
Intervention: En bloc excision of proximal nail fold without nail plate avulsion (Group I)
Number of subjects: 30
Study 12862326 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute caffeine consumption (5 mg x kg(‐1) body mass)
Number of subjects: 16
Study 12862326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic caffeine consumption (5 mg x kg(‐1) body mass for 7 days)
Number of subjects: 16
Study 12862326 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study 10974962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural family intervention
Number of subjects: 0
Study 8998022 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Patient Care (PIPC) nursing care delivery model
Number of subjects: 0
Study 8998022 — intervention group
Group type: COMPARATOR
Intervention: Control nursing units
Number of subjects: 0
Study 8998022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot nursing units
Number of subjects: 0
Study 1595423 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral d-amphetamine
Number of subjects: 8
Study 1595423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31254046 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pelvic floor muscle exercise instruction session supervised by a physical therapist and educational brochures about home-based PFME exercises.
Number of subjects: 202
Study 31254046 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 202
Study 31340232 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg oral midazolam (first session)
Number of subjects: 18
Study 31340232 — intervention group
Group type: COMPARATOR
Intervention: oral placebo (first session)
Number of subjects: 18
Study 27926633 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium+Vitamin D
Number of subjects: 1521
Study 27926633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Number of subjects: 1521
Study 27926633 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium+Vitamin D + Hormone Therapy
Number of subjects: 1521
Study 27926633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1521
Study 26023217 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue massage and exercise (n=40)
Number of subjects: 80
Study 26023217 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (n=40)
Number of subjects: 80
Study 23649576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 0
Study 23649576 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 0
Study 23649576 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 0
Study 23649576 — intervention group
Group type: COMPARATOR
Intervention: Paraffin (Control)
Number of subjects: 0
Study 21074974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 51
Study 21074974 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy
Number of subjects: 51
Study 19556262 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg kg(‐1) day(‐1) for 4 weeks followed by 0.33 mg kg(‐1) day(‐1) for 5 months and azathioprine 2 mg kg(‐1) day(‐1) for 6 months (Group 1)
Number of subjects: 85
Study 19556262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 2)
Number of subjects: 85
Study 17541639 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine co-administered with DTPa-HBV-IPV/Hib vaccine
Number of subjects: 451
Study 17541639 — intervention group
Group type: COMPARATOR
Intervention: MMRV vaccine alone
Number of subjects: 451
Study 17541639 — intervention group
Group type: COMPARATOR
Intervention: Booster dose of DTPa-HBV-IPV/Hib vaccine
Number of subjects: 451
Study 15579570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior heavy-intensity warm-up exercise (Mod2)
Number of subjects: 12
Study 15579570 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise without prior warm-up (Mod1)
Number of subjects: 12
Study 12109633 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d
Number of subjects: 40
Study 12109633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10390000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pamidronate
Number of subjects: 37
Study 7491293 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid vegetable diet (carrot and spinach)
Number of subjects: 20
Study 7491293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable diet (broccoli and cauliflower)
Number of subjects: 20
Study 7491293 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet (tofu and textured vegetable protein product)
Number of subjects: 20
Study 7491293 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (vegetable free)
Number of subjects: 20
Study 7491293 — intervention group
Group type: COMPARATOR
Intervention: Other test diets (carotenoid and cruciferous)
Number of subjects: 20
Study 7491293 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 20
Study 2112943 — intervention group
Group type: EXPERIMENTAL
Intervention: Three minutes of tidal breathing from a Magill breathing system
Number of subjects: 20
Study 2112943 — intervention group
Group type: EXPERIMENTAL
Intervention: Four vital capacity breaths from a non‐rebreathing system
Number of subjects: 20
Study 2112943 — intervention group
Group type: EXPERIMENTAL
Intervention: Four vital capacity breaths from a Magill breathing system
Number of subjects: 20
Study 2112943 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal expiration before application of the face mask with four vital capacity breaths from a Magill system
Number of subjects: 20
Study 419454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's Lactate (RL)
Number of subjects: 29
Study 419454 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin in Ringer's lactate (ALB)
Number of subjects: 29
Study 30509941 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial blood sampling and duplex real‐time quantitative PCR (qPCR)
Number of subjects: 771
Study 30509941 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole arm
Number of subjects: 771
Study 30509941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study 28049201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral adherence promotion program (2 sessions)
Number of subjects: 33
Study 28049201 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 33
Study 25998003 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Flex punctal plugs
Number of subjects: 50
Study 25998003 — intervention group
Group type: COMPARATOR
Intervention: Parasol punctal plugs
Number of subjects: 50
Study 23142309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelargonium sidoides daily for 5 days (n=30)
Number of subjects: 61
Study 23142309 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, n=31)
Number of subjects: 61
Study 21727781 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 33
Study 21727781 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 33
Study 19786405 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanta/Sutter MCP prostheses
Number of subjects: 18
Study 19786405 — intervention group
Group type: COMPARATOR
Intervention: Swanson MCP prostheses
Number of subjects: 18
Study 19786405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 18
Study 16713009 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg/day for 12 weeks
Number of subjects: 55
Study 16713009 — intervention group
Group type: COMPARATOR
Intervention: Control (not administered valsartan)
Number of subjects: 55
Study 14716700 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (up to 10 mg once daily)
Number of subjects: 120
Study 14716700 — intervention group
Group type: COMPARATOR
Intervention: Galantamine (up to 12 mg twice daily)
Number of subjects: 120
Study 11747380 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with lower sodium intake
Number of subjects: 412
Study 11747380 — intervention group
Group type: COMPARATOR
Intervention: Control (typical U.S. diet) with lower sodium intake
Number of subjects: 412
Study 9252210 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 40
Study 9252210 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (mean intake 19.8 g day(-1))
Number of subjects: 40
Study 9252210 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 40
Study 8277143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day
Number of subjects: 89
Study 8277143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 3325229 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg) - Group M2 (2 tablets per day)
Number of subjects: 200
Study 3325229 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg) - Group M3 (3 tablets per day)
Number of subjects: 200
Study 3325229 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate retard (40 mg) - Group D2 (2 tablets per day)
Number of subjects: 200
Study 3325229 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate retard (40 mg) - Group D3 (3 tablets per day)
Number of subjects: 200
Study 3325229 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 200
Study 3325229 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg)
Number of subjects: 200
Study 3325229 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate retard (40 mg)
Number of subjects: 200
Study 29228079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity treadmill exercise (4 days per week, 80%-85% maximum heart rate)
Number of subjects: 128
Study 29228079 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill exercise (4 days per week, 60%-65% maximum heart rate)
Number of subjects: 128
Study 29228079 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 128
Study 27002933 — intervention group
Group type: COMPARATOR
Intervention: Incremental protocol
Number of subjects: 19
Study 27002933 — intervention group
Group type: EXPERIMENTAL
Intervention: Decremental protocol
Number of subjects: 19
Study 23906445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 182
Study 23906445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 23796693 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified sorghum meal (n = 67)
Number of subjects: 132
Study 23796693 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 65)
Number of subjects: 132
Study 20220063 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day
Number of subjects: 210
Study 20220063 — intervention group
Group type: COMPARATOR
Intervention: Imatinib high dose or 400 mg + interferon-alpha
Number of subjects: 210
Study 20220063 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 210
Study 18684418 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus added pharmacist input
Number of subjects: 130
Study 18684418 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 130
Study 15562383 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogens (micronized 17beta‐estradiol; Systen, Janssen‐Cilag, Switzerland) and progesterone
Number of subjects: 61
Study 15562383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormones (Cyclo‐Menorette)
Number of subjects: 61
Study 15562383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 61
Study 12217138 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telecare intervention
Number of subjects: 0
Study 10359391 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione 300 mg/d (n = 10)
Number of subjects: 30
Study 10359391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study 7727473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg intravenously) given three times weekly for the first 6 weeks after transplantation and for another 2 weeks for each treated rejection episode between 6 and 12 weeks.
Number of subjects: 56
Study 7727473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7727473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (10 mg/kg/day for 2 weeks)
Number of subjects: 56
Study 1828447 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 10
Study 1828447 — intervention group
Group type: COMPARATOR
Intervention: Placebo or abstention
Number of subjects: 10
Study 6816064 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 16
Study 6816064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6816064 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 16
Study 6816064 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms
Number of subjects: 16
Study 30337316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up group
Number of subjects: 500
Study 30337316 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 500
Study 27677502 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC-CHO (alcohol and carbohydrate)
Number of subjects: 8
Study 27677502 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC-PRO (alcohol and protein)
Number of subjects: 8
Study 27677502 — intervention group
Group type: COMPARATOR
Intervention: PRO (protein only)
Number of subjects: 8
Study 24899662 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol treatment (10 patients treated for 4 weeks)
Number of subjects: 54
Study 24899662 — intervention group
Group type: COMPARATOR
Intervention: Patients with acute gout not receiving allopurinol
Number of subjects: 54
Study 24899662 — intervention group
Group type: COMPARATOR
Intervention: All patient groups (including controls)
Number of subjects: 54
Study 24899662 — intervention group
Group type: COMPARATOR
Intervention: Controls and patients not receiving allopurinol
Number of subjects: 54
Study 24899662 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients receiving allopurinol
Number of subjects: 54
Study 22565110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group
Number of subjects: 2646
Study 22565110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intensive intervention group
Number of subjects: 2646
Study 22565110 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2646
Study 20594432 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 73
Study 20594432 — intervention group
Group type: COMPARATOR
Intervention: Individually randomised trials
Number of subjects: 73
Study 20594432 — intervention group
Group type: COMPARATOR
Intervention: Cluster randomised trials
Number of subjects: 73
Study 20594432 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 73
Study 18567325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalad orientation of spinal needle (group A)
Number of subjects: 50
Study 18567325 — intervention group
Group type: COMPARATOR
Intervention: Lateral orientation of spinal needle (group B)
Number of subjects: 50
Study 15812265 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81
Study 15812265 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 81
Study 11922217 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma added to grafts
Number of subjects: 3
Study 11922217 — intervention group
Group type: COMPARATOR
Intervention: Control group (grafts without platelet-rich plasma)
Number of subjects: 3
Study 10937931 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan therapy
Number of subjects: 0
Study 10937931 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0
Study 8777826 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium, 50 mg orally
Number of subjects: 10
Study 8777826 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 20 mg orally
Number of subjects: 10
Study 8777826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of losartan and enalapril
Number of subjects: 10
Study 8777826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1381788 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 10